This article is more than 5 years old. Information may no longer be current.
Long-term study data indicates sustained improvement in GERD
Click Here to Manage Email Alerts
ORLANDO, Fla. – The principal investigator of the Stretta procedure has concluded that the procedure is effective in the control of GERD and the reduction of medication requirements 10 years post-procedure.
“The sustained improvement in GERD-HRQL scores and patient satisfaction, coupled with the potential for protection against esophageal cancer, validate the long-term usefulness of this safe, clinically effective and economically effective endoscopic procedure,” said Mark D. Noar, MD, director of Endoscopic Microsurgery Associates, Towson, Md., in a Mederi Therapeutics press release issued here during Digestive Disease Week.
The highlights of the 10-year data are: The statistically significant and sustained improvement in GERD as measured by the HQRL scores, patient satisfaction and reduced medication requirements; patients with variant anatomy and prior anti-reflux surgery responded as well as those with normal anatomy; there was an improvement in Barrett’s tissue; that the reduction in reflux may protect against esophageal cancer, and that the 10-year results are favorable when compared to the Nissen surgery, notably in regards to complications, according to the company press release.
Disclosure: Noar is the principal investigator for Stretta, which is manufactured and marketed by Mederi Therapeutics.